Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 8/20 | 0.87 |
| ▸ | KRAS | P01116 | 8/20 | 0.65 |
| ▸ | TGM2 | P21980 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.59 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphomethylphosphonic Acid Guanosyl Ester SCHEMBL12714656 | 0.93 | NT5E (1.00) | NT5EKRASTGM2PLCG1ENPP1 | |
| Phosphomethylphosphonic Acid Guanosyl Ester SCHEMBL21067782 | 0.93 | NT5E (1.00) | NT5EKRASTGM2PLCG1ENPP1 | |
| Phosphomethylphosphonic Acid Guanosyl Ester SCHEMBL4312033 | 0.93 | NT5E (1.00) | NT5EKRASTGM2PLCG1ENPP1 | |
| Phosphomethylphosphonic Acid Guanosyl Ester SCHEMBL12714637 | 0.93 | NT5E (1.00) | NT5EKRASTGM2PLCG1ENPP1 | |
| SCHEMBL13638720 | 0.91 | NT5E (0.71) | NT5EKRASTGM2POLB | |
| SCHEMBL12714661 | 0.90 | NT5E (0.84) | NT5EKRASTGM2POLBPLCG1 | |
| SCHEMBL26624061 | 0.88 | NT5E (0.81) | NT5EKRASTGM2POLB | |
| SCHEMBL12714665 | 0.88 | NT5E (0.84) | NT5EKRASTGM2POLB | |
| SCHEMBL12714573 | 0.87 | NT5E (0.82) | NT5EKRASTGM2POLB | |
| SCHEMBL4371935 | 0.87 | TGM2 (0.71) | NT5EKRASTGM2POLBENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086813-A1 | COMPOUNDS FOR TREATING BACTERIAL INFECTIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2011-04-14 | — | — | US | disclosed |
| US-20110086813-A1 | COMPOUNDS FOR TREATING BACTERIAL INFECTIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086813-A1 | COMPOUNDS FOR TREATING BACTERIAL INFECTIONS | REL, RELA, NFKB1 | NT5E 492/4885KRAS 176/4885TGM2 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.